Stock comparison
Globus Medical
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMED
Globus Medical
Market cap
$11.44B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMED | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 79B | HALO |
| Benjamin Graham | 65B | 83A | HALO |
| Philip Fisher | 70C | 65B | GMED |
| Peter Lynch | 63C | 53D | GMED |
| Joel Greenblatt | 45D | 40D | GMED |
| Charlie Munger | 51D | 80C | HALO |
| Terry Smith | 56D | 84A | HALO |
Side-by-side metrics
| Metric | GMED | HALO |
|---|---|---|
| Market cap | $11.44B | $8.1B |
| P/E (TTM) | 17.7x | 24.0x |
| EV/EBIT | 20.6x | 10.2x |
| ROIC (TTM) | 9.72% | 23.65% |
| Gross margin | 67.86% | 81.24% |
| Net margin | 18.92% | 23.13% |
| Revenue CAGR 5y | 32.34% | 33.23% |
| EPS CAGR 5y | 28.06% | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMED leads on
- EPS CAGR 5y28.06%vs -1.98%+107%
- Debt / Equity0.0xvs 1.0x+97%
- Market cap$11.44Bvs $8.1B+29%
- P/E (TTM)17.7xvs 24.0x+26%
HALO leads on
- ROIC (TTM)23.65%vs 9.72%+59%
- EV/EBIT10.2xvs 20.6x+51%
- Net margin23.13%vs 18.92%+18%
- Gross margin81.24%vs 67.86%+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.